| Tumor mutational load predicts survival after immunotherapy across multiple cancer types RM Samstein, CH Lee, AN Shoushtari, MD Hellmann, R Shen, ... Nature genetics 51 (2), 202-206, 2019 | 3071 | 2019 |
| Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma RJ Motzer, J Bacik, BA Murphy, P Russo, M Mazumdar Journal of clinical oncology 20 (1), 289-296, 2002 | 2048 | 2002 |
| Guideline for management of the clinical T1 renal mass SC Campbell, AC Novick, A Belldegrun, ML Blute, GK Chow, ... The Journal of urology 182 (4), 1271-1279, 2009 | 2016 | 2009 |
| Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study WC Huang, AS Levey, AM Serio, M Snyder, AJ Vickers, GV Raj, ... The lancet oncology 7 (9), 735-740, 2006 | 1877 | 2006 |
| Epidemiology of renal cell carcinoma U Capitanio, K Bensalah, A Bex, SA Boorjian, F Bray, J Coleman, JL Gore, ... European urology 75 (1), 74-84, 2019 | 1239 | 2019 |
| Partial nephrectomy versus radical nephrectomy in patients with small renal tumors—is there a difference in mortality and cardiovascular outcomes? WC Huang, EB Elkin, AS Levey, TL Jang, P Russo The Journal of urology 181 (1), 55-62, 2009 | 1011 | 2009 |
| Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma RJ Motzer, J Bacik, LH Schwartz, V Reuter, P Russo, S Marion, ... Journal of clinical oncology 22 (3), 454-463, 2004 | 992 | 2004 |
| A postoperative prognostic nomogram for renal cell carcinoma MW KATTAN, V REUTER, RJ MOTZER, J KATZ, P RUSSO The Journal of urology 166 (1), 63-67, 2001 | 905 | 2001 |
| Surgical management of renal tumors 4 cm. or less in a contemporary cohort CT Lee, J Katz, W Shi, HT Thaler, VE Reuter, P Russo The Journal of urology 163 (3), 730-736, 2000 | 857 | 2000 |
| Systemic therapy for renal cell carcinoma RJ Motzer, P Russo The Journal of urology 163 (2), 408-417, 2000 | 838 | 2000 |
| Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures Y Şenbabaoğlu, RS Gejman, AG Winer, M Liu, EM Van Allen, ... Genome biology 17, 1-25, 2016 | 775 | 2016 |
| Resection of metastatic renal cell carcinoma. JP Kavolius, DP Mastorakos, C Pavlovich, P Russo, ME Burt, MS Brady Journal of Clinical Oncology 16 (6), 2261-2266, 1998 | 737 | 1998 |
| Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised … RJ Motzer, BI Rini, DF McDermott, OA Frontera, HJ Hammers, ... The Lancet Oncology 20 (10), 1370-1385, 2019 | 704 | 2019 |
| Natural history of chronic renal insufficiency after partial and radical nephrectomy J McKiernan, R Simmons, J Katz, P Russo Urology 59 (6), 816-820, 2002 | 673 | 2002 |
| An integrated metabolic atlas of clear cell renal cell carcinoma AA Hakimi, ED Reznik, CH Lee, CJ Creighton, AR Brannon, A Luna, ... Cancer cell 29 (1), 104-116, 2016 | 639 | 2016 |
| A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma M Sorbellini, MW Kattan, ME Snyder, V Reuter, R Motzer, M Goetzl, ... The Journal of urology 173 (1), 48-51, 2005 | 617 | 2005 |
| Cystectomy for bladder cancer: a contemporary series G Dalbagni, E Genega, MIA Hashibe, ZF Zhang, P Russo, H Herr, ... The Journal of urology 165 (4), 1111-1116, 2001 | 588 | 2001 |
| Treatment outcome and survival associated with metastatic renal cell carcinoma of non–clear-cell histology RJ Motzer, J Bacik, T Mariani, P Russo, M Mazumdar, V Reuter Journal of Clinical Oncology 20 (9), 2376-2381, 2002 | 565 | 2002 |
| Assessing the impact of ischaemia time during partial nephrectomy F Becker, H Van Poppel, OW Hakenberg, C Stief, I Gill, G Guazzoni, ... European urology 56 (4), 625-635, 2009 | 535 | 2009 |
| Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial CR Divgi, N Pandit-Taskar, AA Jungbluth, VE Reuter, M Gönen, S Ruan, ... The lancet oncology 8 (4), 304-310, 2007 | 436 | 2007 |
